Summary

Chronic Lymphocytic Leukemia Therapeutics Market 2024-2028
The chronic lymphocytic leukemia therapeutics market is forecasted to grow by USD 2.92 bn during 2023-2028, accelerating at a CAGR of 8.82% during the forecast period. The report on the chronic lymphocytic leukemia therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increasing research grants for different blood cancers, the increasing prevalence of chronic lymphocytic leukemia, and the growing geriatric population.
Technavio's chronic lymphocytic leukemia therapeutics market is segmented as below:
By Route Of Administration
• Parenteral
• Oral
By Therapy
• Chemotherapy
• Targeted
• Others
By Geography
• North America
• Europe
• Asia
• Rest of World (ROW)
This study identifies the special drug designations for chronic lymphocytic leukemia therapeutics as one of the prime reasons driving the chronic lymphocytic leukemia therapeutics market growth during the next few years. Also, the rise in R&D activities related to innovative chronic lymphocytic leukemia therapeutics and increased use of predictive biomarkers for diagnosing chronic lymphocytic leukemia will lead to sizable demand in the market.
The report on the chronic lymphocytic leukemia therapeutics market covers the following areas:
• Chronic lymphocytic leukemia therapeutics market sizing
• Chronic lymphocytic leukemia therapeutics market forecast
• Chronic lymphocytic leukemia therapeutics market industry analysis
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading chronic lymphocytic leukemia therapeutics market vendors that include AbbVie Inc., Amgen Inc., AstraZeneca PLC, Biogen Inc., Bristol-Myers Squibb Company, F. Hoffmann La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Novartis AG, Pfizer Inc., R2T BIOPHARMA INC, Sanofi SA, Takeda Pharmaceutical Co. Ltd., and Teva Pharmaceutical Industries Ltd.. Also, the chronic lymphocytic leukemia therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors. For further information on this report, please visit - https://www.technavio.com/report/chronic-lymphocytic-leukemia-therapeutics-market-industry-analysis
The publisher presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources through an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

ページTOPに戻る

Table of Contents

- 1 Executive Summary
o 1.1 Market overview
o Exhibit 01: Executive Summary - Chart on Market Overview
o Exhibit 02: Executive Summary - Data Table on Market Overview
o Exhibit 03: Executive Summary - Chart on Global Market Characteristics
o Exhibit 04: Executive Summary - Chart on Market by Geography
o Exhibit 05: Executive Summary - Chart on Market Segmentation by Route of Administration
o Exhibit 06: Executive Summary - Chart on Market Segmentation by Therapy
o Exhibit 07: Executive Summary - Chart on Incremental Growth
o Exhibit 08: Executive Summary - Data Table on Incremental Growth
o Exhibit 09: Executive Summary - Chart on Vendor Market Positioning
- 2 Market Landscape
o 2.1 Market ecosystem
o Exhibit 10: Parent market
o Exhibit 11: Market Characteristics
- 3 Market Sizing
o 3.1 Market definition
o Exhibit 12: Offerings of vendors included in the market definition
o 3.2 Market segment analysis
o Exhibit 13: Market segments
o 3.3 Market size 2023
o 3.4 Market outlook: Forecast for 2023-2028
o Exhibit 14: Chart on Global - Market size and forecast 2023-2028 ($ billion)
o Exhibit 15: Data Table on Global - Market size and forecast 2023-2028 ($ billion)
o Exhibit 16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
o Exhibit 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)
- 4 Historic Market Size
o 4.1 Global chronic lymphocytic leukemia therapeutics market 2018 - 2022
o Exhibit 18: Historic Market Size - Data Table on global chronic lymphocytic leukemia therapeutics market 2018 - 2022 ($ billion)
o 4.2 Route Of Administration Segment Analysis 2018 - 2022
o Exhibit 19: Historic Market Size - Route Of Administration Segment 2018 - 2022 ($ billion)
o 4.3 Therapy Segment Analysis 2018 - 2022
o Exhibit 20: Historic Market Size - Therapy Segment 2018 - 2022 ($ billion)
o 4.4 Geography Segment Analysis 2018 - 2022
o Exhibit 21: Historic Market Size - Geography Segment 2018 - 2022 ($ billion)
o 4.5 Country Segment Analysis 2018 - 2022
o Exhibit 22: Historic Market Size - Country Segment 2018 - 2022 ($ billion)
- 5 Five Forces Analysis
o 5.1 Five forces summary
o Exhibit 23: Five forces analysis - Comparison between 2023 and 2028
o 5.2 Bargaining power of buyers
o Exhibit 24: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028
o 5.3 Bargaining power of suppliers
o Exhibit 25: Bargaining power of suppliers - Impact of key factors in 2023 and 2028
o 5.4 Threat of new entrants
o Exhibit 26: Threat of new entrants - Impact of key factors in 2023 and 2028
o 5.5 Threat of substitutes
o Exhibit 27: Threat of substitutes - Impact of key factors in 2023 and 2028
o 5.6 Threat of rivalry
o Exhibit 28: Threat of rivalry - Impact of key factors in 2023 and 2028
o 5.7 Market condition
o Exhibit 29: Chart on Market condition - Five forces 2023 and 2028
- 6 Market Segmentation by Route of Administration
o 6.1 Market segments
o Exhibit 30: Chart on Route of Administration - Market share 2023-2028 (%)
o Exhibit 31: Data Table on Route of Administration - Market share 2023-2028 (%)
o 6.2 Comparison by Route of Administration
o Exhibit 32: Chart on Comparison by Route of Administration
o Exhibit 33: Data Table on Comparison by Route of Administration
o 6.3 Parenteral - Market size and forecast 2023-2028
o Exhibit 34: Chart on Parenteral - Market size and forecast 2023-2028 ($ billion)
o Exhibit 35: Data Table on Parenteral - Market size and forecast 2023-2028 ($ billion)
o Exhibit 36: Chart on Parenteral - Year-over-year growth 2023-2028 (%)
o Exhibit 37: Data Table on Parenteral - Year-over-year growth 2023-2028 (%)
o 6.4 Oral - Market size and forecast 2023-2028
o Exhibit 38: Chart on Oral - Market size and forecast 2023-2028 ($ billion)
o Exhibit 39: Data Table on Oral - Market size and forecast 2023-2028 ($ billion)
o Exhibit 40: Chart on Oral - Year-over-year growth 2023-2028 (%)
o Exhibit 41: Data Table on Oral - Year-over-year growth 2023-2028 (%)
o 6.5 Market opportunity by Route of Administration
o Exhibit 42: Market opportunity by Route of Administration ($ billion)
o Exhibit 43: Data Table on Market opportunity by Route of Administration ($ billion)
- 7 Market Segmentation by Therapy
o 7.1 Market segments
o Exhibit 44: Chart on Therapy - Market share 2023-2028 (%)
o Exhibit 45: Data Table on Therapy - Market share 2023-2028 (%)
o 7.2 Comparison by Therapy
o Exhibit 46: Chart on Comparison by Therapy
o Exhibit 47: Data Table on Comparison by Therapy
o 7.3 Chemotherapy - Market size and forecast 2023-2028
o Exhibit 48: Chart on Chemotherapy - Market size and forecast 2023-2028 ($ billion)
o Exhibit 49: Data Table on Chemotherapy - Market size and forecast 2023-2028 ($ billion)
o Exhibit 50: Chart on Chemotherapy - Year-over-year growth 2023-2028 (%)
o Exhibit 51: Data Table on Chemotherapy - Year-over-year growth 2023-2028 (%)
o 7.4 Targeted - Market size and forecast 2023-2028
o Exhibit 52: Chart on Targeted - Market size and forecast 2023-2028 ($ billion)
o Exhibit 53: Data Table on Targeted - Market size and forecast 2023-2028 ($ billion)
o Exhibit 54: Chart on Targeted - Year-over-year growth 2023-2028 (%)
o Exhibit 55: Data Table on Targeted - Year-over-year growth 2023-2028 (%)
o 7.5 Others - Market size and forecast 2023-2028
o Exhibit 56: Chart on Others - Market size and forecast 2023-2028 ($ billion)
o Exhibit 57: Data Table on Others - Market size and forecast 2023-2028 ($ billion)
o Exhibit 58: Chart on Others - Year-over-year growth 2023-2028 (%)
o Exhibit 59: Data Table on Others - Year-over-year growth 2023-2028 (%)
o 7.6 Market opportunity by Therapy
o Exhibit 60: Market opportunity by Therapy ($ billion)
o Exhibit 61: Data Table on Market opportunity by Therapy ($ billion)
- 8 Customer Landscape
o 8.1 Customer landscape overview
o Exhibit 62: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
- 9 Geographic Landscape
o 9.1 Geographic segmentation
o Exhibit 63: Chart on Market share by geography 2023-2028 (%)
o Exhibit 64: Data Table on Market share by geography 2023-2028 (%)
o 9.2 Geographic comparison
o Exhibit 65: Chart on Geographic comparison
o Exhibit 66: Data Table on Geographic comparison
o 9.3 North America - Market size and forecast 2023-2028
o Exhibit 67: Chart on North America - Market size and forecast 2023-2028 ($ billion)
o Exhibit 68: Data Table on North America - Market size and forecast 2023-2028 ($ billion)
o Exhibit 69: Chart on North America - Year-over-year growth 2023-2028 (%)
o Exhibit 70: Data Table on North America - Year-over-year growth 2023-2028 (%)
o 9.4 Europe - Market size and forecast 2023-2028
o Exhibit 71: Chart on Europe - Market size and forecast 2023-2028 ($ billion)
o Exhibit 72: Data Table on Europe - Market size and forecast 2023-2028 ($ billion)
o Exhibit 73: Chart on Europe - Year-over-year growth 2023-2028 (%)
o Exhibit 74: Data Table on Europe - Year-over-year growth 2023-2028 (%)
o 9.5 Asia - Market size and forecast 2023-2028
o Exhibit 75: Chart on Asia - Market size and forecast 2023-2028 ($ billion)
o Exhibit 76: Data Table on Asia - Market size and forecast 2023-2028 ($ billion)
o Exhibit 77: Chart on Asia - Year-over-year growth 2023-2028 (%)
o Exhibit 78: Data Table on Asia - Year-over-year growth 2023-2028 (%)
o 9.6 Rest of World (ROW) - Market size and forecast 2023-2028
o Exhibit 79: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
o Exhibit 80: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
o Exhibit 81: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
o Exhibit 82: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
o 9.7 US - Market size and forecast 2023-2028
o Exhibit 83: Chart on US - Market size and forecast 2023-2028 ($ billion)
o Exhibit 84: Data Table on US - Market size and forecast 2023-2028 ($ billion)
o Exhibit 85: Chart on US - Year-over-year growth 2023-2028 (%)
o Exhibit 86: Data Table on US - Year-over-year growth 2023-2028 (%)
o 9.8 Germany - Market size and forecast 2023-2028
o Exhibit 87: Chart on Germany - Market size and forecast 2023-2028 ($ billion)
o Exhibit 88: Data Table on Germany - Market size and forecast 2023-2028 ($ billion)
o Exhibit 89: Chart on Germany - Year-over-year growth 2023-2028 (%)
o Exhibit 90: Data Table on Germany - Year-over-year growth 2023-2028 (%)
o 9.9 China - Market size and forecast 2023-2028
o Exhibit 91: Chart on China - Market size and forecast 2023-2028 ($ billion)
o Exhibit 92: Data Table on China - Market size and forecast 2023-2028 ($ billion)
o Exhibit 93: Chart on China - Year-over-year growth 2023-2028 (%)
o Exhibit 94: Data Table on China - Year-over-year growth 2023-2028 (%)
o 9.10 Japan - Market size and forecast 2023-2028
o Exhibit 95: Chart on Japan - Market size and forecast 2023-2028 ($ billion)
o Exhibit 96: Data Table on Japan - Market size and forecast 2023-2028 ($ billion)
o Exhibit 97: Chart on Japan - Year-over-year growth 2023-2028 (%)
o Exhibit 98: Data Table on Japan - Year-over-year growth 2023-2028 (%)
o 9.11 UK - Market size and forecast 2023-2028
o Exhibit 99: Chart on UK - Market size and forecast 2023-2028 ($ billion)
o Exhibit 100: Data Table on UK - Market size and forecast 2023-2028 ($ billion)
o Exhibit 101: Chart on UK - Year-over-year growth 2023-2028 (%)
o Exhibit 102: Data Table on UK - Year-over-year growth 2023-2028 (%)
o 9.12 Market opportunity by geography
o Exhibit 103: Market opportunity by geography ($ billion)
o Exhibit 104: Data Tables on Market opportunity by geography ($ billion)
- 10 Drivers, Challenges, and Trends
o 10.1 Market drivers
o 10.2 Market challenges
o 10.3 Impact of drivers and challenges
o Exhibit 105: Impact of drivers and challenges in 2023 and 2028
o 10.4 Market trends
- 11 Vendor Landscape
o 11.1 Overview
o 11.2 Vendor landscape
o Exhibit 106: Overview on Criticality of inputs and Factors of differentiation
o 11.3 Landscape disruption
o Exhibit 107: Overview on factors of disruption
o 11.4 Industry risks
o Exhibit 108: Impact of key risks on business
- 12 Vendor Analysis
o 12.1 Vendors covered
o Exhibit 109: Vendors covered
o 12.2 Market positioning of vendors
o Exhibit 110: Matrix on vendor position and classification
o 12.3 AbbVie Inc.
o Exhibit 111: AbbVie Inc. - Overview
o Exhibit 112: AbbVie Inc. - Product / Service
o Exhibit 113: AbbVie Inc. - Key news
o Exhibit 114: AbbVie Inc. - Key offerings
o 12.4 Amgen Inc.
o Exhibit 115: Amgen Inc. - Overview
o Exhibit 116: Amgen Inc. - Product / Service
o Exhibit 117: Amgen Inc. - Key offerings
o 12.5 AstraZeneca PLC
o Exhibit 118: AstraZeneca PLC - Overview
o Exhibit 119: AstraZeneca PLC - Product / Service
o Exhibit 120: AstraZeneca PLC - Key news
o Exhibit 121: AstraZeneca PLC - Key offerings
o 12.6 Biogen Inc.
o Exhibit 122: Biogen Inc. - Overview
o Exhibit 123: Biogen Inc. - Product / Service
o Exhibit 124: Biogen Inc. - Key news
o Exhibit 125: Biogen Inc. - Key offerings
o 12.7 Bristol-Myers Squibb Company
o Exhibit 126: Bristol-Myers Squibb Company - Overview
o Exhibit 127: Bristol-Myers Squibb Company - Product / Service
o Exhibit 128: Bristol-Myers Squibb Company - Key news
o Exhibit 129: Bristol-Myers Squibb Company - Key offerings
o 12.8 F. Hoffmann La Roche Ltd.
o Exhibit 130: F. Hoffmann La Roche Ltd. - Overview
o Exhibit 131: F. Hoffmann La Roche Ltd. - Business segments
o Exhibit 132: F. Hoffmann La Roche Ltd. - Key news
o Exhibit 133: F. Hoffmann La Roche Ltd. - Key offerings
o Exhibit 134: F. Hoffmann La Roche Ltd. - Segment focus
o 12.9 Gilead Sciences Inc.
o Exhibit 135: Gilead Sciences Inc. - Overview
o Exhibit 136: Gilead Sciences Inc. - Product / Service
o Exhibit 137: Gilead Sciences Inc. - Key news
o Exhibit 138: Gilead Sciences Inc. - Key offerings
o 12.10 GlaxoSmithKline Plc
o Exhibit 139: GlaxoSmithKline Plc - Overview
o Exhibit 140: GlaxoSmithKline Plc - Business segments
o Exhibit 141: GlaxoSmithKline Plc - Key news
o Exhibit 142: GlaxoSmithKline Plc - Key offerings
o Exhibit 143: GlaxoSmithKline Plc - Segment focus
o 12.11 Novartis AG
o Exhibit 144: Novartis AG - Overview
o Exhibit 145: Novartis AG - Business segments
o Exhibit 146: Novartis AG - Key news
o Exhibit 147: Novartis AG - Key offerings
o Exhibit 148: Novartis AG - Segment focus
o 12.12 Pfizer Inc.
o Exhibit 149: Pfizer Inc. - Overview
o Exhibit 150: Pfizer Inc. - Product / Service
o Exhibit 151: Pfizer Inc. - Key news
o Exhibit 152: Pfizer Inc. - Key offerings
o 12.13 R2T BIOPHARMA INC
o Exhibit 153: R2T BIOPHARMA INC - Overview
o Exhibit 154: R2T BIOPHARMA INC - Product / Service
o Exhibit 155: R2T BIOPHARMA INC - Key offerings
o 12.14 Sanofi SA
o Exhibit 156: Sanofi SA - Overview
o Exhibit 157: Sanofi SA - Business segments
o Exhibit 158: Sanofi SA - Key news
o Exhibit 159: Sanofi SA - Key offerings
o Exhibit 160: Sanofi SA - Segment focus
o 12.15 Takeda Pharmaceutical Co. Ltd.
o Exhibit 161: Takeda Pharmaceutical Co. Ltd. - Overview
o Exhibit 162: Takeda Pharmaceutical Co. Ltd. - Product / Service
o Exhibit 163: Takeda Pharmaceutical Co. Ltd. - Key news
o Exhibit 164: Takeda Pharmaceutical Co. Ltd. - Key offerings
o 12.16 Teva Pharmaceutical Industries Ltd.
o Exhibit 165: Teva Pharmaceutical Industries Ltd. - Overview
o Exhibit 166: Teva Pharmaceutical Industries Ltd. - Business segments
o Exhibit 167: Teva Pharmaceutical Industries Ltd. - Key news
o Exhibit 168: Teva Pharmaceutical Industries Ltd. - Key offerings
o Exhibit 169: Teva Pharmaceutical Industries Ltd. - Segment focus
- 13 Appendix
o 13.1 Scope of the report
o 13.2 Inclusions and exclusions checklist
o Exhibit 170: Inclusions checklist
o Exhibit 171: Exclusions checklist
o 13.3 Currency conversion rates for US$
o Exhibit 172: Currency conversion rates for US$
o 13.4 Research methodology
o Exhibit 173: Research methodology
o Exhibit 174: Validation techniques employed for market sizing
o Exhibit 175: Information sources
o 13.5 List of abbreviations
o Exhibit 176: List of abbreviations